The third sector in the Pharmaceutical industry – we definitely are talking about a lot of mergers and acquisitions and cost pressures in that space. And the Pharma industry is definitely challenged at the moment, and probably will be for quite a few years to come. However, what we are addressing in the pharmaceutical industry is a question, which is a tremendously important indoor quest to increase the development efficiency that has definitely been lagging over the last few years.
Our Molecular Technologies are used in clinical trials, are used to profile patients, to select patients, to monitor diseases progression and to provide better answers for better drug development. We are seeing great growth in this area, in the clinical research phase, which is primarily in the pharmaceuticals sector, but increasingly also in the academic sector.
And the reason why we’re getting premium growth in this space is because we have this crossover between academic and clinical portfolios. So products that basically can be use for both types of applications and fulfill the quality and regulatory requirements for both areas and we are also putting onto those portfolios content.
So the fact that we today have about 60,000 assays that can be blasted against clinical samples and almost seamlessly be transitioned into clinical products under the same roof is a tremendous benefit for our customers in Pharma and in clinical research in Academia.Let me talk about some of these pillars in a little bit more detail. But before we go there, our position in general is one that we see as an opportunity to simplify, to accelerate and to improve the process from taking a raw biological sample, here a draw of blood, into digital information. And there are 100s of different options to do that. That diversity is constantly underestimated.